Showing 4,541 - 4,560 results of 4,776 for search '"Gastroenterology"', query time: 0.11s Refine Results
  1. 4541

    Omentin-1, a Protective Adipokine for Irritable Bowel Syndrome by Gao Y, Chen C, Huang X, Liu Y, Zhou Z, Pan Y

    Published 2025-02-01
    “…Yanping Gao,1,2,* Chen Chen,1,2,* Xijing Huang,2 Ya Liu,1 Zhou Zhou,1 Yan Pan1 1Department of Gastroenterology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, People’s Republic of China; 2Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yan Pan; Zhou Zhou, Sichuan Provincial People’s Hospital, 32 The First Ring Road West 2, Chengdu, Sichuan, 610072, People’s Republic of China, Email panyan2211@163.com; doublezhou2006@126.comIntroduction: Irritable bowel syndrome (IBS) is characterized by patients’ high level of suffering. …”
    Get full text
    Article
  2. 4542
  3. 4543
  4. 4544
  5. 4545

    Factors influencing the natural history of non-IgE-mediated gastrointestinal food allergies in paediatric age: a prospective multicentre cohort study by Giorgio Bedogni, Roberto Berni Canani, Laura Carucci, Rita Nocerino, Serena Coppola, Pasqualina Capasso, Veronica Giglio

    Published 2025-02-01
    “…Background We aimed at identifying the factors influencing the natural history of non-IgE-mediated gastrointestinal food allergies (non-IgE-GIFA), a group of common paediatric conditions including food protein–induced: enteropathy (FPE), allergic proctocolitis (FPIAP), enterocolitis syndrome (FPIES), and motility disorders (FPIMD).Methods Prospective multicentre cohort study involving paediatric patients (both sexes, aged ≤14 y) with non-IgE-GIFA diagnosed and followed for 24 months at a Tertiary Centre for Paediatric Allergy, Gastroenterology and Nutrition. Anamnestic and clinical data were collected from all enrolled patients.Results 123 non-IgE-GIFA patients were enrolled (56% male, median age (IQR) 150 (60–300) days): FPE (39%), FPIES (17%), FPIAP (16%) and FPIMD (28%). 42% of patients had multiple food allergies (FAs) at baseline, and 64% had a positive family history of allergy. …”
    Get full text
    Article
  6. 4546
  7. 4547
  8. 4548
  9. 4549

    The Effects of Digital eHealth Versus Onsite 2-Day Group-Based Education in 255 Patients With Irritable Bowel Syndrome: Cohort Study by Birgitte Berentsen, Camilla Thuen, Eline Margrete Randulff Hillestad, Elisabeth Kjelsvik Steinsvik, Trygve Hausken, Jan Gunnar Hatlebakk

    Published 2025-02-01
    “…MethodsPatients diagnosed with IBS, aged 15-70 years, were enrolled after referral to the Section of Gastroenterology at Haukeland University Hospital, Norway. …”
    Get full text
    Article
  10. 4550
  11. 4551
  12. 4552
  13. 4553
  14. 4554
  15. 4555
  16. 4556
  17. 4557
  18. 4558

    Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States by Finn RS, Iyer R, Kalman RS, Parikh ND, Cabrera R, Babajanyan S, Kaseb AO

    Published 2025-02-01
    “…Richard S Finn,1 Renuka Iyer,2 Richard S Kalman,3 Neehar D Parikh,4 Roniel Cabrera,5 Svetlana Babajanyan,6 Ahmed O Kaseb7 1Department of Medicine, University of California, Los Angeles, CA, USA; 2Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA; 3Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA; 4Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA; 5Department of Medicine, University of Florida Health, Gainesville, FL, USA; 6US Medical Affairs, Oncology, Bayer Healthcare, Whippany, NJ, USA; 7Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence: Richard S Finn, Department of Medicine, University of California, Los Angeles, CA, USA, Tel +1-310-586-2091, Email rfinn@mednet.ucla.eduIntroduction: While several systemic therapies are available for unresectable hepatocellular carcinoma (uHCC), there is a lack of granular real-world evidence to support the efficacy and safety of these therapies. …”
    Get full text
    Article
  19. 4559
  20. 4560